In a recent update on May 5, 2025, HC Wainwright & Co. has reiterated its "Buy" rating for Tourmaline Bio (TRML, Financial). The analyst Yi Chen maintained the price target at $50.00, indicating confidence in the stock's potential growth.
The price target prior to this update was also $50.00, showing no change in the analyst's expectation for the stock's performance. Yi Chen has consistently held the price target steady, reflecting a stable outlook for TRML.
The stock continues to be rated as a "Buy", further suggesting that Tourmaline Bio (TRML, Financial) may present a promising investment opportunity. Investors should take note of HC Wainwright & Co.'s steadfast stance on TRML as they consider their stock portfolio strategies.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Tourmaline Bio Inc (TRML, Financial) is $53.56 with a high estimate of $65.00 and a low estimate of $35.00. The average target implies an upside of 228.56% from the current price of $16.30. More detailed estimate data can be found on the Tourmaline Bio Inc (TRML) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Tourmaline Bio Inc's (TRML, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
